A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

NCT00480935 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped poor recruitment

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Sunitinib Malate (Sutent)

Sponsor

University Health Network, Toronto

Collaborators

[object Object]